TAR 200

Drug Profile

TAR 200

Alternative Names: Gemcitabine-releasing intravesical system - TARIS; GemRIS; TAR-200

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator AstraZeneca; TARIS Biomedical
  • Developer TARIS Biomedical
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bladder cancer

Most Recent Events

  • 06 Jan 2017 TARIS Biomedical closes enrollment in a phase Ib trial in Bladder cancer in USA due to early positive results
  • 10 Aug 2016 Phase-I clinical trials in Bladder cancer (Non-muscle invasive) in Netherlands (Intravesicular, Controlled release) , NCT02720367)
  • 01 Apr 2016 Phase-I clinical trials in Bladder cancer in USA (Intravesicular, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top